The CTGF gene ?45?G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes
详细信息 查看全文
- 作者：Sheila K Patel (1)
Bryan Wai (1) (2)
Richard J MacIsaac (3)
Sharon Grant (1)
Elena Velkoska (1)
Michelle Ord (2)
Sianna Panagiotopoulos (4)
George Jerums (1) (4)
Piyush M Srivastava (1) (2)
Louise M Burrell (1) (2) - 关键词：Type 2 diabetes ; Connective tissue growth factor ; CTGF ; Cardiac fibrosis ; Chronic kidney disease.
- 刊名：Cardiovascular Diabetology
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：11
- 期：1
- 全文大小：250KB
- 参考文献：1. Ban CR, Twigg SM: Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. / Vasc Health Risk Manag 2008, 4:575-96.
2. Leask A: Getting to the heart of the matter: CCN2 plays a role in cardiomyocyte hypertrophy. / J Cell Commun Signal 2010, 4:73-4. href="http://dx.doi.org/10.1007/s12079-009-0061-7">CrossRef
3. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA: Connective tissue growth factor and cardiac fibrosis. / Acta Physiol (Oxf) 2009, 195:321-38. href="http://dx.doi.org/10.1111/j.1748-1716.2008.01936.x">CrossRef
4. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH: CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. / J Mol Cell Cardiol 2000, 32:1805-819. href="http://dx.doi.org/10.1006/jmcc.2000.1215">CrossRef
5. Hayata N, Fujio Y, Yamamoto Y, Iwakura T, Obana M, Takai M, Mohri T, Nonen S, Maeda M, Azuma J: Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. / Biochem Biophys Res Commun 2008, 370:274-78. href="http://dx.doi.org/10.1016/j.bbrc.2008.03.100">CrossRef
6. Igarashi A, Okochi H, Bradham DM, Grotendorst GR: Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. / Mol Biol Cell 1993, 4:637-45.
7. Dean RG, Balding LC, Candido R, Burns WC, Cao Z, Twigg SM, Burrell LM: Connective tissue growth factor and cardiac fibrosis after myocardial infarction. / J Histochem Cytochem 2005, 53:1245-256. href="http://dx.doi.org/10.1369/jhc.4A6560.2005">CrossRef
8. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM: A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. / Circ Res 2003, 92:785-92. href="http://dx.doi.org/10.1161/01.RES.0000065620.39919.20">CrossRef
9. Au CG, Butler TL, Sherwood MC, Egan JR, North KN, Winlaw DS: Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. / Int J Exp Pathol 2011, 92:57-5. href="http://dx.doi.org/10.1111/j.1365-2613.2010.00750.x">CrossRef
10. Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ, Wakasaki H, King GL: Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. / Diabetes 2002, 51:2709-718. href="http://dx.doi.org/10.2337/diabetes.51.9.2709">CrossRef
11. Galderisi M, Anderson KM, Wilson PW, Levy D: Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). / Am J Cardiol 1991, 68:85-9. href="http://dx.doi.org/10.1016/0002-9149(91)90716-X">CrossRef
12. Struthers AD, Morris AD: Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. / Lancet 2002, 359:1430-432. href="http://dx.doi.org/10.1016/S0140-6736(02)08358-7">CrossRef
13. Srivastava PM, Calafiore P, Macisaac RJ, Patel SK, Thomas MC, Jerums G, Burrell LM: Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes. / Clin Sci (Lond) 2008, 114:313-20. href="http://dx.doi.org/10.1042/CS20070261">CrossRef
14. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? / Kidney Int 1999, 56:1627-637. href="http://dx.doi.org/10.1046/j.1523-1755.1999.00721.x">CrossRef
15. Wahab NA, Yevdokimova N, Weston BS, Roberts T, Li XJ, Brinkman H, Mason RM: Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. / Biochem J 2001, 359:77-7. href="http://dx.doi.org/10.1042/0264-6021:3590077">CrossRef
16. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R: Expression of connective tissue growth factor in human renal fibrosis. / Kidney Int 1998, 53:853-61. href="http://dx.doi.org/10.1111/j.1523-1755.1998.00820.x">CrossRef
17. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. / J Am Soc Nephrol 2000, 11:25-8.
18. Roestenberg P, van Nieuwenhoven FA, Wieten L, Boer P, Diekman T, Tiller AM, Wiersinga WM, Oliver N, Usinger W, Weitz S, Schlingemann RO, Goldschmeding R: Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. / Diabetes Care 2004, 27:1164-170. href="http://dx.doi.org/10.2337/diacare.27.5.1164">CrossRef
19. Nguyen TQ, Tarnow L, Jorsal A, Oliver N, Roestenberg P, Ito Y, Parving HH, Rossing P, van Nieuwenhoven FA, Goldschmeding R: Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. / Diabetes Care 2008, 31:1177-182. href="http://dx.doi.org/10.2337/dc07-2469">CrossRef
20. Gilbert RE, Akdeniz A, Weitz S, Usinger WR, Molineaux C, Jones SE, Langham RG, Jerums G: Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. / Diabetes Care 2003, 26:2632-636. href="http://dx.doi.org/10.2337/diacare.26.9.2632">CrossRef
21. Blom IE, van Dijk AJ, de Weger RA, Tilanus MG, Goldschmeding R: Identification of human ccn2 (connective tissue growth factor) promoter polymorphisms. / Mol Pathol 2001, 54:192-96. href="http://dx.doi.org/10.1136/mp.54.3.192">CrossRef
22. Fonseca C, Lindahl GE, Ponticos M, Sestini P, Renzoni EA, Holmes AM, Spagnolo P, Pantelidis P, Leoni P, McHugh N, Stock CJ, Shi-Wen X, Denton CP, Black CM, Welsh KI, du Bois RM, Abraham DJ: A polymorphism in the CTGF promoter region associated with systemic sclerosis. / N Engl J Med 2007, 357:1210-220. href="http://dx.doi.org/10.1056/NEJMoa067655">CrossRef
23. Patel SK, Wai B, Ord M, Macisaac RJ, Grant S, Velkoska E, Panagiotopoulos S, Jerums G, Srivastava PM, Burrell LM: Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in caucasians with type 2 diabetes. / Am J Hypertens 2012, 25:216-22. href="http://dx.doi.org/10.1038/ajh.2011.188">CrossRef
24. American Diabetes Association: Standards of medical care in diabetes--2012. / Diabetes Care 2012,35(Suppl 1):S11-S63.
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. / Ann Intern Med 1999, 130:461-70.
26. Levey AS, Coresh J: Chronic kidney disease. / Lancet 2012, 379:165-80. href="http://dx.doi.org/10.1016/S0140-6736(11)60178-5">CrossRef
27. Brosius FC, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, Pennathur S, Smith GL, Wilson PW: Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. / Circulation 2006, 114:1083-087. href="http://dx.doi.org/10.1161/CIRCULATIONAHA.106.177321">CrossRef
28. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. / J Am Soc Echocardiogr 2005, 18:1440-463. href="http://dx.doi.org/10.1016/j.echo.2005.10.005">CrossRef
29. Srivastava PM, Thomas MC, Calafiore P, MacIsaac RJ, Jerums G, Burrell LM: Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. / Clin Sci (Lond) 2006, 110:109-16. href="http://dx.doi.org/10.1042/CS20050184">CrossRef
30. International HapMap Consortium: The International HapMap Project. / Nature 2003, 426:789-96. href="http://dx.doi.org/10.1038/nature02168">CrossRef
31. Meune C, Vignaux O, Kahan A, Allanore Y: Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. / Arch Cardiovasc Dis 2010, 103:46-2. href="http://dx.doi.org/10.1016/j.acvd.2009.06.009">CrossRef
32. Gourh P, Mayes MD, Arnett FC: CTGF polymorphism associated with systemic sclerosis. / N Engl J Med 2008, 358:308-09. href="http://dx.doi.org/10.1056/NEJMc072958">CrossRef
33. Louthrenoo W, Kasitanon N, Wichainun R, Wangkaew S, Sukitawut W, Ohnogi Y, Kuwata S, Takeuchi F: Lack of CTGF*-945C/G Dimorphism in Thai Patients with Systemic Sclerosis. / Open Rheumatol J 2011, 5:59-3. href="http://dx.doi.org/10.2174/1874312901105010059">CrossRef
34. Rueda B, Simeon C, Hesselstrand R, Herrick A, Worthington J, Ortego-Centeno N, Riemekasten G, Fonollosa V, Vonk MC, van den Hoogen FH, Sanchez-Roman J, Aguirre-Zamorano MA, Garcia-Portales R, Pros A, Camps MT, Gonzalez-Gay MA, Gonzalez-Escribano MF, Coenen MJ, Lambert N, Nelson JL, Radstake TR, Martin J: A large multicentre analysis of CTGF ?45 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype. / Ann Rheum Dis 2009, 68:1618-620. href="http://dx.doi.org/10.1136/ard.2008.100180">CrossRef
35. Tu E, Bagnall RD, Duflou J, Lynch M, Twigg SM, Semsarian C: Post-mortem pathologic and genetic studies in "dead in bed syndrome" cases in type 1 diabetes mellitus. / Hum Pathol 2010, 41:392-00. href="http://dx.doi.org/10.1016/j.humpath.2009.08.020">CrossRef
36. Dendooven A, Nguyen TQ, Brosens L, Li D, Tarnow L, Parving HH, Rossing P, Goldschmeding R: The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes. / J Negat Results Biomed 2011, 10:4. href="http://dx.doi.org/10.1186/1477-5751-10-4">CrossRef
37. McKnight AJ, Savage DA, Patterson CC, Brady HR, Maxwell AP: Resequencing of the characterised CTGF gene to identify novel or known variants, and analysis of their association with diabetic nephropathy. / J Hum Genet 2006, 51:383-86. href="http://dx.doi.org/10.1007/s10038-006-0368-7">CrossRef
38. Wang B, Carter RE, Jaffa MA, Nakerakanti S, Lackland D, Lopes-Virella M, Trojanowska M, Luttrell LM, Jaffa AA: Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. / J Med Genet 2010, 47:391-97. href="http://dx.doi.org/10.1136/jmg.2009.073098">CrossRef
39. Cozzolino M, Biondi ML, Banfi E, Riser BL, Mehmeti F, Cusi D, Gallieni M: CCN2 (CTGF) gene polymorphism is a novel prognostic risk factor for cardiovascular outcomes in hemodialysis patients. / Blood Purif 2010, 30:272-76. href="http://dx.doi.org/10.1159/000320706">CrossRef
40. Pivovarova O, Fisher E, Dudziak K, Ilkavets I, Dooley S, Slominsky P, Limborska S, Weickert MO, Spranger J, Fritsche A, Boeing H, Pfeiffer AF, Rudovich N: A polymorphism within the connective tissue growth factor (CTGF) gene has no effect on non-invasive markers of beta-cell area and risk of type 2 diabetes. / Dis Markers 2011, 31:241-46.
41. Brooks BA, Franjic B, Ban CR, Swaraj K, Yue DK, Celermajer DS, Twigg SM: Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. / Diabetes Obes Metab 2008, 10:739-46. href="http://dx.doi.org/10.1111/j.1463-1326.2007.00803.x">CrossRef
42. Lu TM, Lin SJ, Lin MW, Hsu CP, Chung MY: The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. / Cardiovasc Diabetol 2011, 10:16. href="http://dx.doi.org/10.1186/1475-2840-10-16">CrossRef
43. Opstad TB, Pettersen AA, Arnesen H, Seljeflot I: Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an Observational Study. / Cardiovasc Diabetol 2011, 10:110. href="http://dx.doi.org/10.1186/1475-2840-10-110">CrossRef
44. Cresci S, Wu J, Province MA, Spertus JA, Steffes M, McGill JB, Alderman EL, Brooks MM, Kelsey SF, Frye RL, Bach RG: Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diabetes trial. / Circulation 2011, 124:1426-434. href="http://dx.doi.org/10.1161/CIRCULATIONAHA.111.029173">CrossRef
45. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E: Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. / J Cardiovasc Magn Reson 2008, 10:35. href="http://dx.doi.org/10.1186/1532-429X-10-35">CrossRef - 作者单位：Sheila K Patel (1)
Bryan Wai (1) (2)
Richard J MacIsaac (3)
Sharon Grant (1)
Elena Velkoska (1)
Michelle Ord (2)
Sianna Panagiotopoulos (4)
George Jerums (1) (4)
Piyush M Srivastava (1) (2)
Louise M Burrell (1) (2)
1. Department of Medicine, Austin Health, University of Melbourne, Level 7, Lance Townsend Building, 145 Studley Road, Melbourne, VIC, 3084, Australia
2. Department of Cardiology, Austin Health, Melbourne, Australia
3. Department of Endocrinology and Diabetes, St Vincent’s Hospital, Victoria, Australia
4. Endocrine Centre of Excellence, Austin Health, Melbourne, Australia
文摘
Background Connective tissue growth factor (CTGF) has been implicated in the cardiac and kidney complications of type 2 diabetes, and the CTGF ?/em>945?G/C polymorphism is associated with susceptibility to systemic sclerosis, a disease characterised by tissue fibrosis. This study investigated the association of the CTGF ?/em>945?G/C promoter variant with cardiac complications (left ventricular (LV) hypertrophy (LVH), diastolic and systolic dysfunction) and chronic kidney disease (CKD) in type 2 diabetes. Methods The CTGF ?/em>945?G/C polymorphism (rs6918698) was examined in 495 Caucasian subjects with type 2 diabetes. Cardiac structure and function were assessed by transthoracic echocardiography. Kidney function was assessed using estimated glomerular filtration rate (eGFR) and albuminuria, and CKD defined as the presence of kidney damage (decreased kidney function (eGFR <60?ml/min/1.73?m2) or albuminuria). Results The mean age?±?SD of the cohort was 62?±-4?years, with a body mass index (BMI) of 31?±-?kg/m2 and median diabetes duration of 11?years [25th, 75th interquartile range; 5, 18]. An abnormal echocardiogram was present in 73% of subjects; of these, 8% had LVH alone, 74% had diastolic dysfunction and 18% had systolic?±?diastolic dysfunction. CKD was present in 42% of subjects. There were no significant associations between the CTGF ?/em>945?G/C polymorphism and echocardiographic parameters of LV mass or cardiac function, or kidney function both before and after adjustment for covariates of age, gender, BMI, blood pressure and hypertension. CTGF ?/em>945 genotypes were not associated with the cardiac complications of LVH, diastolic or systolic dysfunction, nor with CKD. Conclusions In Caucasians with type 2 diabetes, genetic variation in the CTGF ?/em>945?G/C polymorphism is not associated with cardiac or kidney complications.